Clinical Trial Update: Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating whether an ABCG2 gene mutation influences teriflunomide exposure and safety in Chinese patients with relapsing-remitting multi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• AUBAGIO (TERIFLUNOMIDE)

Snippet

Sponsor: Sanofi | Conditions: Multiple Sclerosis | Phase 4 | Status: COMPLETED